Clinical trial

Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus…

NCT00002035 · Bristol-Myers Squibb, Industry · Completed

Key facts

NCT number NCT00002035
Title Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
Official title Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
Lead sponsor Bristol-Myers Squibb, Industry
Status Completed
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Zidovudine, Didanosine
Enrollment 300
Completion Apr 1, 1992
First posted Aug 31, 2001
Last update posted Aug 5, 2011
Countries Puerto Rico, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies